14.53
+1(+7.39%)
Currency In USD
| Previous Close | 13.53 |
| Open | 13.68 |
| Day High | 15.26 |
| Day Low | 13.39 |
| 52-Week High | 65.8 |
| 52-Week Low | 2.62 |
| Volume | 850,483 |
| Average Volume | 1.61M |
| Market Cap | 99.59M |
| PE | -0.04 |
| EPS | -386.86 |
| Moving Average 50 Days | 16.23 |
| Moving Average 200 Days | 22.47 |
| Change | 1 |
If you invested $1000 in Vor Biopharma Inc. (VOR) since IPO date, it would be worth $387.47 as of December 24, 2025 at a share price of $14.53. Whereas If you bought $1000 worth of Vor Biopharma Inc. (VOR) shares 3 years ago, it would be worth $2,310.02 as of December 24, 2025 at a share price of $14.53.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Vor Bio Appoints RA Capital’s Andrew Levin, M.D., Ph.D., and Forbion’s Wouter Joustra to Board of Directors
GlobeNewswire Inc.
Yesterday at 9:01 PM GMT
BOSTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Vor Biopharma Inc. (Nasdaq: VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced the appointment of Andrew Levin, M.D., Ph.D.,
Vor Bio Announces $150 Million Private Placement
GlobeNewswire Inc.
Dec 15, 2025 1:00 PM GMT
BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it has entered into a securities purchase agreement to sell 13,876,032 s
Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire Inc.
Nov 13, 2025 9:01 PM GMT
Multiple Late-Stage Data Readouts Reinforce Telitacicept’s Broad Potential Across Autoimmune DiseasesExpansion of Executive Leadership and Board Strengthens Global Development Capabilities Expected gross proceeds of $115 million raised in the Novembe